Reproducibility of the Dobutamine-Atropine echocardiography stress test

P. Bellotti, P. M. Fioretti, T. Forster, A. J. McNeill, M. E S El Said, A. Salustri, J. R T C Roelandt, Said El Said

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

To assess the reproducibility of dobutamine-atropine echocardiography testing, two studies (1 to 20 days apart [mean 3.3 days]) were performed in 23 patients with stable effort angina pectoris or chest pain. During the study, 20 (87%) patients were receiving beta blockers alone or combined with nitrates or calcium antagonists. Dobutamine was infused at doses of 10,μg/kgper minute every 3 minutes up to a maximum of 40,μg/kgper minute and this maximal dose was continued for 6 minutes. Inpatients not achieving 85% predicted maximal heart rate or myocardial ischemia, atropine (0.25-1 mg) was added and dobutamine continued for another 3 minutes, until either an adequate heart rate was achieved or the test was considered positive. During dobutamine infusion, electrocardiographic, echocardiographic, and blood pressure monitoring were obtained in each patient. Side effects including tremor, nausea, palpitation, dizziness, headache, and nonsustained ventricular tachycardia occurred in three patients. The same symptoms, but no ventricular tachycardia, developed during the same stage of the second test. Angina pectoris (eight patients), electrocardiographic changes (six patients), and ischemic wall-motion abnormalities (six patients) were observed at the same stage of the two tests. The mean values of heart rate, blood pressure, and rate-pressure product were comparable for each stage in duplicate tests. Our data show that pharmacological stress echocardiography using dobutamine-atropine has good reproducibility and provides a useful tool for assessing disease progression and the effects of therapeutic interventions in patients with coronary artery disease. (ECHOCARDIOGRAPHY, Volume 10, January 1993)

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalEchocardiography
Volume10
Issue number1
Publication statusPublished - 1993

Fingerprint

Dobutamine
Atropine
Exercise Test
Echocardiography
Heart Rate
Ventricular Tachycardia
Blood Pressure
Stress Echocardiography
Stable Angina
Angina Pectoris
Dizziness
Tremor
Therapeutic Uses
Chest Pain
Nausea
Myocardial Ischemia
Headache
Disease Progression
Inpatients
Coronary Artery Disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Bellotti, P., Fioretti, P. M., Forster, T., McNeill, A. J., El Said, M. E. S., Salustri, A., ... El Said, S. (1993). Reproducibility of the Dobutamine-Atropine echocardiography stress test. Echocardiography, 10(1), 93-97.

Reproducibility of the Dobutamine-Atropine echocardiography stress test. / Bellotti, P.; Fioretti, P. M.; Forster, T.; McNeill, A. J.; El Said, M. E S; Salustri, A.; Roelandt, J. R T C; El Said, Said.

In: Echocardiography, Vol. 10, No. 1, 1993, p. 93-97.

Research output: Contribution to journalArticle

Bellotti, P, Fioretti, PM, Forster, T, McNeill, AJ, El Said, MES, Salustri, A, Roelandt, JRTC & El Said, S 1993, 'Reproducibility of the Dobutamine-Atropine echocardiography stress test', Echocardiography, vol. 10, no. 1, pp. 93-97.
Bellotti P, Fioretti PM, Forster T, McNeill AJ, El Said MES, Salustri A et al. Reproducibility of the Dobutamine-Atropine echocardiography stress test. Echocardiography. 1993;10(1):93-97.
Bellotti, P. ; Fioretti, P. M. ; Forster, T. ; McNeill, A. J. ; El Said, M. E S ; Salustri, A. ; Roelandt, J. R T C ; El Said, Said. / Reproducibility of the Dobutamine-Atropine echocardiography stress test. In: Echocardiography. 1993 ; Vol. 10, No. 1. pp. 93-97.
@article{197369e19dbe468d8b6b8fbffbd8b7b7,
title = "Reproducibility of the Dobutamine-Atropine echocardiography stress test",
abstract = "To assess the reproducibility of dobutamine-atropine echocardiography testing, two studies (1 to 20 days apart [mean 3.3 days]) were performed in 23 patients with stable effort angina pectoris or chest pain. During the study, 20 (87{\%}) patients were receiving beta blockers alone or combined with nitrates or calcium antagonists. Dobutamine was infused at doses of 10,μg/kgper minute every 3 minutes up to a maximum of 40,μg/kgper minute and this maximal dose was continued for 6 minutes. Inpatients not achieving 85{\%} predicted maximal heart rate or myocardial ischemia, atropine (0.25-1 mg) was added and dobutamine continued for another 3 minutes, until either an adequate heart rate was achieved or the test was considered positive. During dobutamine infusion, electrocardiographic, echocardiographic, and blood pressure monitoring were obtained in each patient. Side effects including tremor, nausea, palpitation, dizziness, headache, and nonsustained ventricular tachycardia occurred in three patients. The same symptoms, but no ventricular tachycardia, developed during the same stage of the second test. Angina pectoris (eight patients), electrocardiographic changes (six patients), and ischemic wall-motion abnormalities (six patients) were observed at the same stage of the two tests. The mean values of heart rate, blood pressure, and rate-pressure product were comparable for each stage in duplicate tests. Our data show that pharmacological stress echocardiography using dobutamine-atropine has good reproducibility and provides a useful tool for assessing disease progression and the effects of therapeutic interventions in patients with coronary artery disease. (ECHOCARDIOGRAPHY, Volume 10, January 1993)",
author = "P. Bellotti and Fioretti, {P. M.} and T. Forster and McNeill, {A. J.} and {El Said}, {M. E S} and A. Salustri and Roelandt, {J. R T C} and {El Said}, Said",
year = "1993",
language = "English",
volume = "10",
pages = "93--97",
journal = "Echocardiography",
issn = "0742-2822",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Reproducibility of the Dobutamine-Atropine echocardiography stress test

AU - Bellotti, P.

AU - Fioretti, P. M.

AU - Forster, T.

AU - McNeill, A. J.

AU - El Said, M. E S

AU - Salustri, A.

AU - Roelandt, J. R T C

AU - El Said, Said

PY - 1993

Y1 - 1993

N2 - To assess the reproducibility of dobutamine-atropine echocardiography testing, two studies (1 to 20 days apart [mean 3.3 days]) were performed in 23 patients with stable effort angina pectoris or chest pain. During the study, 20 (87%) patients were receiving beta blockers alone or combined with nitrates or calcium antagonists. Dobutamine was infused at doses of 10,μg/kgper minute every 3 minutes up to a maximum of 40,μg/kgper minute and this maximal dose was continued for 6 minutes. Inpatients not achieving 85% predicted maximal heart rate or myocardial ischemia, atropine (0.25-1 mg) was added and dobutamine continued for another 3 minutes, until either an adequate heart rate was achieved or the test was considered positive. During dobutamine infusion, electrocardiographic, echocardiographic, and blood pressure monitoring were obtained in each patient. Side effects including tremor, nausea, palpitation, dizziness, headache, and nonsustained ventricular tachycardia occurred in three patients. The same symptoms, but no ventricular tachycardia, developed during the same stage of the second test. Angina pectoris (eight patients), electrocardiographic changes (six patients), and ischemic wall-motion abnormalities (six patients) were observed at the same stage of the two tests. The mean values of heart rate, blood pressure, and rate-pressure product were comparable for each stage in duplicate tests. Our data show that pharmacological stress echocardiography using dobutamine-atropine has good reproducibility and provides a useful tool for assessing disease progression and the effects of therapeutic interventions in patients with coronary artery disease. (ECHOCARDIOGRAPHY, Volume 10, January 1993)

AB - To assess the reproducibility of dobutamine-atropine echocardiography testing, two studies (1 to 20 days apart [mean 3.3 days]) were performed in 23 patients with stable effort angina pectoris or chest pain. During the study, 20 (87%) patients were receiving beta blockers alone or combined with nitrates or calcium antagonists. Dobutamine was infused at doses of 10,μg/kgper minute every 3 minutes up to a maximum of 40,μg/kgper minute and this maximal dose was continued for 6 minutes. Inpatients not achieving 85% predicted maximal heart rate or myocardial ischemia, atropine (0.25-1 mg) was added and dobutamine continued for another 3 minutes, until either an adequate heart rate was achieved or the test was considered positive. During dobutamine infusion, electrocardiographic, echocardiographic, and blood pressure monitoring were obtained in each patient. Side effects including tremor, nausea, palpitation, dizziness, headache, and nonsustained ventricular tachycardia occurred in three patients. The same symptoms, but no ventricular tachycardia, developed during the same stage of the second test. Angina pectoris (eight patients), electrocardiographic changes (six patients), and ischemic wall-motion abnormalities (six patients) were observed at the same stage of the two tests. The mean values of heart rate, blood pressure, and rate-pressure product were comparable for each stage in duplicate tests. Our data show that pharmacological stress echocardiography using dobutamine-atropine has good reproducibility and provides a useful tool for assessing disease progression and the effects of therapeutic interventions in patients with coronary artery disease. (ECHOCARDIOGRAPHY, Volume 10, January 1993)

UR - http://www.scopus.com/inward/record.url?scp=0027475691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027475691&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 93

EP - 97

JO - Echocardiography

JF - Echocardiography

SN - 0742-2822

IS - 1

ER -